819813-71-3

Basic information

• Product Name: Benzoic acid, 3,4-bis(2-methoxyethoxy)-
• CAS NO: 819813-71-3
• Molecular Formula: C13H18O6
• Molecular Weight: 270.282
• Mol File: 819813-71-3.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 3,4-bis(2-methoxyethoxy)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 3,4-bis(2-methoxyethoxy)-(819813-71-3)
• EPA Substance Registry System: Benzoic acid, 3,4-bis(2-methoxyethoxy)-(819813-71-3)

Safety Data

• Hazardous Substances Data: 819813-71-3(Hazardous Substances Data)

Upstream product

• 121-33-5 vanillin 
• 139-85-5 3,4-dihydroxybenzaldehyde 
• 80407-64-3 3,4-bis(2-methoxyethoxy)benzaldehyde 
• 99-50-3 3,4-Dihydroxybenzoic acid 
• 627-42-9 2-chloroethyl methyl ether 
• 179688-14-3 methyl 3,4-bis{[2-(methyloxy)ethyl]oxy}benzoate 
• 2150-43-8 3,4-dihydroxybenzoic acid methyl ester 
• 183322-16-9 3,4-bis(2-methoxyethoxy)benzoic acid ethyl ester 
• 3943-89-3 Ethyl protocatechuate 

Downstream Products

• 80407-68-7 3,4-bis(2-methoxyethoxy)-benzonitrile 
• 236750-65-5 4,5-bis(2-methoxyethoxy)-2-nitrobenzonitrile 
• 1418289-91-4 3,4-bis(2-methoxyethoxy)-benzamide 
• 950596-58-4 2-amino-4,5-bis-(2-methoxyethoxy)-benzonitrile 
• 950596-59-5 N′-[2-cyano-4,5-{bis(2-methoxyethoxy)phenyl}]-N,N-dimethylformamidine 
• 183321-74-6 erlotinib 
• 183319-69-9 erlotinib hydrochloride 
• 179688-29-0 6,7-bis(2-methoxyethoxy)-3,4-dihydroquinazolin-4-one 
• 179688-27-8 ethyl 2-amino-4,5-bis(2-methoxyethoxy)-benzoate 
• 1447828-82-1 N¹-(6,7-bis(2-methoxyethoxy)quinazolin-4-yl)-N³,N³-bis(2-chloroethyl)benzene-1,3-diamine hydrochloride 
• 179688-26-7 2-nitro-4,5-bis(2-methoxyethoxy)benzoic acid ethyl ester 
• 183322-16-9 3,4-bis(2-methoxyethoxy)benzoic acid ethyl ester 
• 501684-22-6 methyl 4,5-bis(2-methoxyethoxy)-2-nitrobenzoate 
• 476168-17-9 2-amino-4,5-bis-(2-methoxyethoxy)-benzoic acid methyl ester 

Relevant articles and documents

KINASE INHIBITORS

Compounds that inhibit kinase Lck or Btk, pharmaceutically acceptable salts, hydrides, stereoisomers and pharmaceutical compositions thereof are disclosed.

Preparation method of erlotinib intermediate

The invention relates to a preparation method of an erlotinib intermediate. The method concretely comprises the following steps: 1, dissolving vanillin in an organic solvent I, adding aluminum trichloride, adding pyridine in a dropwise manner, and reacting to obtain ELTA; 2, dissolving the ELTA in an organic solvent II, adding 2-chloroethylmethyl ether, potassium carbonate and a phase transfer catalyst, and reacting to obtain ELTB; 3, adding the ELTB to water, adding an alkali and potassium permanganate, and reacting to obtain ELTC; 4, adding concentrated sulfuric acid to methanol in a dropwise manner, adding the ELTC to the above reaction system, and reacting to obtain ELTD; 5, adding concentrated sulfuric acid to concentrated nitric acid in a dropwise manner, dissolving the ELTD in an organic solvent IV, adding a prepared mixed acid to the reaction system, and reacting to obtain ELTE; 6, adding the ELTE, iron powder and ammonium chloride to an organic solvent V, adding concentrated hydrochloric acid in a dropwise manner, and reacting to obtain ELTF; and 7, adding the ELTF, trimethyl orthoformate and ammonium acetate to an organic solvent VI, and reacting to obtain the erlotinib intermediate.

An improved convergent approach for synthesis of erlotinib, a tyrosine kinase inhibitor, via a ring closure reaction of phenyl benzamidine intermediate

An improved convergent and economical method has been developed for the synthesis of erlotinib, a 4-anilinoquinazoline and an EGFR-tyrosine kinase inhibitor for treatment of non-small-cell lung cancer. The final two steps for the formation of this 4-anilinoquinazoline from suitable 2-aminobenzonitrile intermediate and 3-ethynylaniline were modified and were performed in a simple one-pot reaction. The ring-closing mechanism for the formation of erlotinib from the suitable formamidine intermediate and 3-ethynylaniline was investigated and determined to proceed via the formation of phenyl benzamidine intermediate rather than involving Dimroth rearrangement reported earlier. The new benzamidine intermediate was isolated for the first time and characterized. Copyright